Brief: Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium
16/01/2024 22:30
Jan 16 (Reuters) - Leap Therapeutics Inc LPTX.O :
* LEAP THERAPEUTICS INC - 30% ORR AND 93% DCR ACROSS
HETEROGENOUS
SECOND-LINE CRC PATIENTSTREATED WITH DKN-01 PLUS BEVACIZUMAB AND
CHEMOTHERAPY
* LEAP THERAPEUTICS:DATA FROM PART A DEFIANCE STUDY SHOWS
ADDITION
OF DKN-01 TO BEVACIZUMAB & CHEMOTHERAPY CAN GENERATE CLINICALLY
MEANINGFUL RESPONSE RATES
Source text for Eikon: ID:nPnb3qM58a
Further company coverage: LPTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cypherpunk Technologies
See all newsCypherpunk Technologies Inc reports results for the quarter ended June 30 - Earnings Summary
Cypherpunk Technologies swings to Q2 profit on Zcash gains
Cypherpunk Technologies Inc expected to post a loss of 3 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia